Cancer Immunology, Immunotherapy

Search all Cancer Immunology, Immunotherapy articles

Volume 69, Issue 7

July 2020

21 articles in this issue

Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer
Masaki Shiota
Naohiro Fujimoto
Masatoshi Eto
Original Article 02 March 2020 Pages: 1155 - 1163
Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach
Anat Globerson Levin
Natalie Kronik
Vladimir Vainstein
Original Article 04 March 2020 Pages: 1165 - 1175
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
Abdul Rafeh Naqash
Biagio Ricciuti
Paul R. Walker
Original Article 05 March 2020 Pages: 1177 - 1187
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
Abdul Rafeh Naqash
Biagio Ricciuti
Paul R. Walker
Correction 28 April 2020 Pages: 1189 - 1189
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
Tali Voloshin
Noa Kaynan
Yoram Palti
Original Article Open access 06 March 2020 Pages: 1191 - 1204
Adenosine-producing regulatory B cells in head and neck cancer
Sandra S. Jeske
Matthias Brand
Patrick J. Schuler
Original Article Open access 07 March 2020 Pages: 1205 - 1216
Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo
Anja Tatjana Teck
Sabrina Urban
Sebastian Ochsenreither
Original Article Open access 10 March 2020 Pages: 1217 - 1227
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer
Ryota Shibaki
Shuji Murakami
Yuichiro Ohe
Original Article 10 March 2020 Pages: 1229 - 1236
Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets
Diana Tronik-Le Roux
Mathilde Sautreuil
Edgardo D. Carosella
Original Article 12 March 2020 Pages: 1237 - 1252
Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes
Asmaa M. Zahran
Helal F. Hetta
Omnia El-Badawy
Original Article 13 March 2020 Pages: 1253 - 1263
Tumor immune microenvironment in cancer patients with leukocytosis
Kyung Hwan Kim
Nam Suk Sim
Yong Bae Kim
Original Article 13 March 2020 Pages: 1265 - 1277
Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APC^Min/+ mice
Louis Szeponik
Paulina Akeus
Marianne Quiding-Järbrink
Original Article Open access 17 March 2020 Pages: 1279 - 1292
Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis
Guoshu Bi
Zhencong Chen
Hong Fan
Original Article 18 March 2020 Pages: 1293 - 1305
Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target
Said Farschtschi
Lan Kluwe
Andreas Kurtz
Original Article Open access 19 March 2020 Pages: 1307 - 1313
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients
Maya Dadiani
Daniela Necula
Adit Ben-Baruch
Original Article 20 March 2020 Pages: 1315 - 1326
Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8⁺ T cells in gastric cancer
Ruochen Li
Heng Zhang
Jiejie Xu
Original Article 21 March 2020 Pages: 1327 - 1336
In vivo anti-MUC1⁺ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies
Edward Pichinuk
Michael Chalik
Daniel H. Wreschner
Original Article 26 March 2020 Pages: 1337 - 1352
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas
Martin F. Orth
Veit Leonhard Buecklein
Thomas Knösel
Original Article 28 March 2020 Pages: 1353 - 1362
Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas
Christoph Arolt
Moritz Meyer
Jens Peter Klussmann
Original Article Open access 30 March 2020 Pages: 1363 - 1373
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
Qian-Ting Wang
Ying Nie
You-Wen He
Clinical Trial Report 20 February 2020 Pages: 1375 - 1387
Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients
Alessandra Battaglia
Alexia Buzzonetti
Christopher Nicodemus
Correction 26 March 2020 Pages: 1389 - 1389

Volume 69, Issue 7

Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer

Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

Adenosine-producing regulatory B cells in head and neck cancer

Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo

Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer

Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets

Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes

Tumor immune microenvironment in cancer patients with leukocytosis

Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APC^Min/+ mice

Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis

Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target

TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients

Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8⁺ T cells in gastric cancer

In vivo anti-MUC1⁺ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas

Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas

Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Journal navigation